Impact Global Health | G-FINDER

EID R&D MATRIX

WHO scientific framework: viral families with priority/prototype pathogens[i]		Basic research	Drugs	Vaccines	Biologics	Diagnostics	Vector control products
Arenaviridae (including Lassa fever)	*Mammarenavirus lassaense* - Lassa fever	✓	✓	✓	✓	✓	✓‡
	Multiple arenaviral haemorrhagic fevers	✓	✓	✓	✓	✓	✓‡
Bunyaviridae (including CCHF, HTNV, RVF, SFTS)	*Orthonairovirus haemorrhagiae* - Crimean-Congo Haemorrhagic Fever (CCHF)	✓	✓	✓	✓	✓	✓
	Orthohantavirus hantanense - Hantaan virus (HTNV)	✓	✓	✓	✓	✓	✓
	Phlebovirus riftense - Rift Valley Fever (RVF)	✓	✓	✓	✓	✓	✓
	Bandavirus dabieense - Severe Fever with Thrombocytopenia Syndrome (SFTS)	✓	✓	✓	✓	✓	✓
	Multiple bunyaviral diseases	✓	✓	✓	✓	✓	✓
Coronaviridae (including COVID-19, MERS)	*Subgenus Merbecoviruses* - Middle East Respiratory Syndrome (MERS)	✓	✓	✓	✓	✓	✓‡
	Subgenus Sarbecoviruses - Coronavirus disease 2019 (COVID-19)	✓	✓	✓	✓	✓	✓‡
	Multiple coronaviral diseases[1]	✓	✓	✓	✓	✓	✓‡
Filoviridae (including Ebola, Marburg)	*Orthoebolavirus zairense and Orthoebolavirus sudanens* - Ebola	✓	✓	✓	✓	✓	✓‡
	Orthomarburgvirus marburgense - Marburg	✓	✓	✓	✓	✓	✓‡
	Multiple filoviral diseases	✓	✓	✓	✓	✓	✓‡
Flaviviridae (including Dengue, Zika)	*Orthoflavivirus denguei* - Dengue^	✓	✓	✓#	✓	✓	✓
	Orthoflavivirus zikaense - Zika	✓	✓	✓	✓	✓	✓
Orthomyxoviridae (including Influenza A)	*Alphainfluenzavirus Influenzae* - Highly pathogenic avian influenza A(H5N1)	✓	✓	✓	✓	✓	✓‡
Paramyxoviridae (Henipaviruses - including Nipah)	*Henipavirus nipahense* - Nipah	✓	✓	✓	✓	✓	✓‡
	Multiple henipaviral diseases	✓	✓	✓	✓	✓	✓‡
Poxviridae (including Mpox)	*Orthopoxvirus monkeypox* - Mpox	✓	✓	✓	✓	✓	✓‡
Togaviridae (including Alphaviruses e.g. CHIKV)	*Alphavirus chikungunya* - Chikungunya (CHIKV)	✓	✓	✓	✓	✓	✓
	Multiple alphaviral diseases	✓	✓	✓	✓	✓	✓

Investment applicable to more than one emerging infectious disease, or to more than one global health area*

Platform technologies					Fundamental research	Multi-disease vector control	Core funding of a multi-disease R&D organisation
Adjuvants & immunomodulators	Biologics-related platform technologies	Drug-related platform technologies	General diagnostic platforms & multi-disease diagnostics	Vaccine-related platform technologies			
✓	✓	✓	✓	✓	✓	✓	✓

[i] The G-FINDER EID survey scope aligns with the World Health Organization's Scientific Framework for Epidemic and Pandemic Research Preparedness., incorporating priority/prototype pathogens from the framework as italicized subcategories within the EID scope matrix. The 'multiple disease categories' capture R&D for two or more pathogens within a viral family

✓denotes a category where a disease or product is included in the survey.

[1] R&D that involves multiple coronaviruses, including SARS-CoV-1, should be captured under multiple coronaviral diseases.

* The G-FINDER project covers three global health areas: neglected diseases, emerging infectious diseases, and sexual & reproductive health issues.

^ Dengue is captured through the G-FINDER neglected disease survey. R&D involving both zika and dengue fall under R&D for both NDs and EIDs.
# Dengue vaccine is restricted to LMIC-specific R&D, including clinical trials, registration and Phase IV studies in the target LMICs
‡ The vector control product (VCP) category consists of three sub-categories: chemical VCPs, biological VCPs, and reservoir-targeted vaccines. Their inclusion depends on whether the pathogen is vector-borne and if an animal reservoir is present. In these non-vector borne diseases, vector control product category includes only veterinary vaccines specifically developed to prevent animal to human transmission

The G-FINDER project also tracks R&D for neglected diseases (NDs), and sexual & reproductive health (SRH) issues. Some of the emerging infectious diseases, issues, products and technologies may overlap with the scope of these other global health areas.